文献速递类风湿关节炎

代谢综合征、脂肪因子与类风湿关节炎先进治疗应答的关系

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2024-12-04

在CorEvitas注册的CERTAIN队列中,2368例启动TNFi或非TNFi生物制剂的类风湿关节炎患者里,687例(29%)有代谢综合征。代谢综合征与6个月时达到CDAI最小临床重要差值(MCID)的较低几率相关(OR 0.69,95%CI 0.56-0.86,P=0.001),且随代谢综合征组分数目呈剂量依赖性下降;脂肪因子与MCID达标无关。

要点

  • 代谢综合征与先进治疗6个月CDAI MCID达标几率降低相关(OR 0.69)。
  • 代谢综合征组分数目越多,应答率呈剂量依赖性下降。
  • 脂肪因子与代谢综合征强相关,但与临床应答无关。

核心结论

  • 代谢综合征与类风湿关节炎启动先进治疗后的较低应答率相关,TNFi与非TNFi生物制剂的效果相似。
  • 脂肪因子与代谢综合征强相关,但与临床应答无关。

研究设计与样本

  • 研究纳入CorEvitas注册中CERTAIN队列里启动TNFi或非TNFi生物制剂治疗的类风湿关节炎参与者。
  • 代谢综合征按美国国家胆固醇教育计划成人治疗组III定义判定。
  • 脂肪因子在200例应答者与无应答者的储存样本子样本中检测。
  • 主要结局为6个月时达到临床疾病活动指数(CDAI)最小临床重要差值(MCID)的变化。

主要发现

  • 2368例参与者中687例(29%)有代谢综合征。
  • 代谢综合征与达到CDAI MCID的较低几率相关(OR 0.69,95%CI 0.56-0.86,P=0.001),且随代谢综合征组分数目呈剂量依赖性应答率下降。
  • 代谢综合征的模型拟合优于体重指数。
  • 代谢综合征与MCID达标的关联在TNFi组(OR 0.65,95%CI 0.49-0.87,P=0.003)与非TNFi治疗组(OR 0.76,95%CI 0.55-1.04,P=0.08;交互作用P=0.49)之间相似。
  • 脂肪因子与MCID达标无关联。

关键数值与推荐

  • 代谢综合征定义采用美国国家胆固醇教育计划成人治疗组III标准。
  • 主要结局阈值:6个月时CDAI变化达到MCID。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We determined if metabolic syndrome, its components, and adipokines (adiponectin, leptin, and fibroblast growth factor-21) were associated with response to advanced therapies among patients with rheumatoid arthritis (RA). METHODS: This study included participants with RA initiating either tumor necrosis factor inhibitor (TNFi) or non-TNFi biologic therapies from the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) cohort within the CorEvitas registry. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III definition. Adipokines were assessed on stored samples from a subsample of responders and nonresponders (n = 200). The primary outcome was the achievement of a change as large as the minimal clinically important difference (MCID) for the Clinical Disease Activity Index (CDAI) at 6 months. RESULTS: Among 2,368 participants, 687 (29%) had metabolic syndrome. Metabolic syndrome was associated with lower odds of achieving CDAI MCID (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.56-0.86, P = 0.001) with a dose-dependent decrease in response rate according to the number of components present. Model fit was superior for metabolic syndrome compared with body mass index. Associations between metabolic syndrome and MCID achievement were similar between patients receiving TNFi (OR 0.65, 95% CI 0.49-0.87, P = 0.003) versus non-TNF therapies (OR 0.76, 95% CI 0.55-1.04, P = 0.08 [P for interaction = 0.49]). Adipokines were not associated with MCID achievement. CONCLUSION: Metabolic syndrome is associated with lower response rates with the initiation of an advanced therapy in RA, with similar effects for both TNFi and non-TNFi agents. Adipokines were strongly associated with metabolic syndrome but were not associated with clinical response.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Baker JF, Reed G, Mikuls TR, et al. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2024. PMID: 39420627. doi:10.1002/art.43034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。